Indaptus Therapeutics is trading 5.66% up in pre-market at $1.12 after August 13, 2026, second-quarter results showed net loss narrowing to approximately $1.8 million from $5.2 million.
- Research and development expenses fell 83%, supporting the earnings improvement.
- The company reported $11.6 million in cash, cash equivalents, and short-term investments after a June private placement.
- It has no active clinical development programs and is evaluating strategic alternatives for Decoy20 and broader operations.